Core Viewpoint - Xianle Health has submitted its application for a mainboard listing on the Hong Kong Stock Exchange, aiming to tap into both A-share and H-share markets, despite facing significant challenges such as halved profits, high debt ratios, and ongoing losses in non-core businesses [1][19]. Financial Performance - Xianle Health has experienced a significant decline in profits, with net profit expected to drop by 53%-69% in 2025, resulting in a projected profit of between 1.01 billion and 1.51 billion RMB, marking the worst performance since its listing [3][19]. - The company reported revenues of 35.82 billion RMB and 42.11 billion RMB for 2023 and 2024, respectively, but the growth trend reversed in 2025, with a 36.25% year-on-year decline in net profit to 1.53 billion RMB in the first three quarters [3][19]. Business Structure and Market Position - Xianle Health has established a business model characterized by "domestic contraction and overseas expansion," with revenue from mainland China and Hong Kong decreasing from 51.7% in 2023 to 38.8% in 2025, while revenue from overseas markets increased from 48.3% to 61.2% in the same period [4][22]. - The company holds 184 global patents and has developed over 6,000 mature formulas, maintaining deep collaborations with seven of the top ten global health food brands and two major pharmaceutical companies [2][21]. Operational Challenges - The company faces operational pressures due to an imbalance in its business structure, external environmental pressures, and internal management fluctuations, particularly in its personal care segment, which has seen a significant drop in customer demand and increased operational costs due to U.S.-China trade tensions [4][6][22]. - Xianle Health's gross margin has been adversely affected by the performance of its core products, with soft capsules and gummies accounting for about 70% of revenue but showing lower profitability compared to competitors [6][25]. Debt and Cash Flow - The company's debt ratio has increased from 50.6% in 2023 to 55.1% in the first three quarters of 2025, indicating rising financial pressure compared to competitors with debt ratios around 20% [9][26]. - Operating cash flow has declined from 5.66 billion RMB in 2024 to 3.22 billion RMB in the first three quarters of 2025, highlighting tightening liquidity [9][26]. Fundraising History - Xianle Health has raised a total of 2.044 billion RMB through two rounds of fundraising since its A-share listing, with a significant portion allocated to debt repayment and working capital [10][27]. - The company plans to use proceeds from its Hong Kong IPO to build new production facilities and expand globally, despite existing underutilized capacity [14][29]. Strategic Transformation - The company attempted to diversify into personal care products, establishing a subsidiary that has since become a financial burden, leading to significant losses and asset impairment provisions totaling 2.52 billion RMB [16][31]. - Despite the potential growth in the global health food market, Xianle Health's efforts to pivot into new areas have not yet yielded positive results, further exacerbating financial pressures [30][32].